P PRIMESTOCKFINDER.COM

MYX Shares Mayne Pharma Group Limited

ASX · ASX
$2.42 -2.42% Prices as of close 2026-10-27

Last in our picks 2026-10-21 — not in the current list; analysis below is from that screen

Specialty-pharma portfolio and resolved Imvexxy litigation improve earnings visibility and strategic optionality.

Future value: $4.50 (+77.17%) · 6-12 months · analyst consensus

Signal breakdown

  • ▸US patent litigation settlement removes overhang
  • ▾Below 50-day MA (-13.98%)
  • ▾Near 52-week low (11.7% of range)
  • ▸~77% upside to price target

Is MYX a buy right now?

Trend: MYX is trading below the 50-day average (-16.26%), RSI 38 — neutral momentum, with a 3-month return of -6.92%.

Valuation & quality: Mayne Pharma Group Limited trades on a trailing P/E of 7.6, forward P/E -6.4, PEG 2.52, price-to-book 0.50; fundamentals show net margin 6.4%, return on equity 8.2%, revenue growth -12.0% year on year.

Analyst consensus: 2 analysts have a mean 12-month price target of A$4.45 (+83.9% vs the last close; range A$3.65 – A$5.25), consensus rating “none”.

Our screen: BUY (score 2) — Specialty-pharma portfolio and resolved Imvexxy litigation improve earnings visibility and strategic optionality.

Computed from end-of-day data; not personal advice.

12-month price chart

3.35 2.13 FebMarAprMayJunJulAugSepOct
Daily close, 2026-02-08 → 2026-10-26 (AUD). Range 2.13 – 3.35.

Monthly returns

Mar 26Apr 26May 26Jun 26Jul 26Aug 26Sep 26Oct 26
-4.80%+18.30%-15.50%+16.30%-4.70%+16.50%-5.80%-17.10%

Fundamentals

Market cap
$198.2M
P/E (ttm)
7.6
Forward P/E
-6.4
EPS (ttm)
$0.32
Price / book
0.50
PEG
2.52
Beta
1.02
Net margin
6.4%
ROE
8.2%
Revenue growth
-12.0%
Revenue (ttm)
$383.7M
Free cash flow
$37.7M
Debt / equity
11%
52-wk range
$2.04 – $6.25
Volume
35,178
Avg volume (3m)
221,379

Analyst price target

Mean target
$4.45
Low
$3.65
High
$5.25
Analysts
2
Consensus
NONE

Technical signals

RSI (14)
38.2
vs 50-day MA
-16.26%
1-mo return
-14.49%
3-mo return
-6.92%
Volume z-score
-0.41

About Mayne Pharma Group Limited

Mayne Pharma Group Limited, a specialty pharmaceutical company, focuses on the commercialization of women's health and dermatology pharmaceuticals in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. It operates through three segments: Women's Health, Dermatology, and International.

Sector: Healthcare · Industry: Medical Distribution · Australia · 363 employees · Website

Related Biotech picks

CSL.AXCSL LimitedMSB.AXMesoblast LimitedIMR.AXImricor Medical SystemSLD.AXSaluda Medical, Inc.NUZ.AXNeurizon Therapeutics NEU.AXNeuren PharmaceuticalsDXB.AXDimerix LimitedNYR.AXNyrada Inc.

Browse: all ASX stocks · Biotech picks · today's movers

General information only (Australia). This is general information, not financial product advice. It doesn't consider your objectives, financial situation or needs — consider its appropriateness and seek licensed advice before acting. Not a recommendation to buy or sell any financial product.

Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.